Completed COVID-19 vaccination among the prioritized groups by territorial entitiy in Colombia

Esquemas completos aplicados contra COVID-19 priorizados por entidad territorial en Colombia

Introduction: Colombia registered the first case of SARS-CoV-2 infection on March 6 2020. A general feeling of fear on the risk of continuing usual vaccination programs in times of COVID-19 and how this could negatively impact on the SARS-CoV-2 infection term, was also faced during the quarantine. Objective: to measure progress withSARS-CoV-2 vaccination among prioritized populations, as well as the proportion of completed vaccination and vaccination percentage of this target population, by territorial entities in Colombia, in the period from February 17 to July 26 2021. Methodology: a cross-sectional study research. Data was obtained from the Ministry of Health and Social Protection website based on the national COVID-19 vaccination plan. Results: the territorial entities with the highest population in the priority vaccination groups were: Antioquia (2’583.113), Bogota (2’077.324), Valle del Cauca (1’437.805), Cundinamarca (1’095.364) and Santander (797.740); among the territorial entities with the highest proportion of people who have received completed vaccination schedules were: Bogota (1’168.212), Antioquia (620.133), Valle del Cauca (576.283), Santander (335.015) and Norte de Santander (232.110). It was concluded that the territories with the highest vaccination percentage in the prioritized groups were: Amazonas (128%), Vaupes (119.92%), Guainia (93,6%), Bogota (56,24%) and Quindio (51, 73%). Conclusion: monitoring the results of completed vaccination at the territorial level is essential to gain understanding on the effectiveness, a possible drop of immune response over time, and the potential adverse consequences of these vaccines.

1. Ministerio de Salud y Protección Social de Colombia. Boletín de Prensa No 050 de 2020: Colombia confirma su primer caso de COVID-19 [Internet]. Ministerio de Salud y Protección Social de Colombia; Colombia. 2020 [Consultado 3 de mayo 2021]. Disponible en: https://www.minsalud.gov.co/Paginas/Colombia-confirma-su-primer-caso-de-COVID-19.aspx
2. Wolff GG. Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season. Vaccine. 2020;38(2):350-354. doi: 10.1016/j.vaccine.2019.10.005
3. Díaz Pinzón JE. Estimación de la prevalencia del COVID-19 en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):99–102. https://doi.org/10.31260/RepertMedCir.01217372.1115
4. Díaz Pinzón JE. Análisis de los resultados del contagio del COVID-19 respecto a su distribución geográfica en Colombia. Repert Med Cir. 2020;29(Núm. Supl.1):60–64. https://doi.org/10.31260/RepertMedCir.01217372.1082
5. Cataño JC, Aguirre HD. Vacunación del adulto en tiempos de COVID-19. Corporación de Investigaciones Biológicas. 2020;1(2):1-9.
6. Priesemann V, Brinkmann MM, Ciesek S, Cuschieri S, Czypionka T, et al. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet. 2021;397(10269):92-93. doi: 10.1016/S0140-6736(20)32625-8
7. Priesemann V, Balling R, Brinkmann MM, Ciesek S, Czypionka T, et al. An action plan for pan-European defence against new SARS-CoV-2 variants. Lancet. 2021;397(10273):469-470. doi: 10.1016/S0140-6736(21)00150-1
8. Davies NG, Abbott S, Barnard RC, Jarvis CI Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538):eabg3055. doi: 10.1126/science.abg3055
9. Abbott S, Funk S, CMMID COVID-19 Working Group. Local area reproduction numbers and S-gene target failure [Internet]. Centre for Mathematical Modelling of Infectious Diseases; 2021 [citado 14 mayo 2021]. Disponible: https://cmmid.github.io/topics/covid19/local-r-sgtf.html
10. Horby P, Huntley C, Davies N, Edmunds J, et al. NERVTAG paper on COVID-19 variant of concern B.1.1.7 [Internet]. Department of Health and Social Care and Scientific Advisory Group for Emergencies; 2021 [citado 14 mayo 2021]. Disponible en: https://www.gov.uk/government/publications/nervtag-paper-on-covid-19-variant-of-concern-b117.
11. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371(6532):916–921. doi: 10.1126/science.abe6959
12. Ramos AM, Vela-Pérez M, Ferrández MR, Kubik AB, Ivorra, B. Modeling the impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. Commun Nonlinear Sci Numer Simul. 2021;102:105937. doi: 10.1016/j.cnsns.2021.105937
13. Ministerio de Salud y Protección Social de Colombia. Plan de vacunación nacional contra COVID-19 [Internet]. Ministerio de Salud y Protección Social de Colombia; Colombia. 2021 [Consultado 3 de mayo 2021]. Disponible en: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx
14. Díaz Pinzón JE. Dinámica y relación del contagio del COVID-19 después de iniciado el plan de vacunación contra el SARS-COV-2 en Colombia. Repert Med Cir. 2021;30(Núm. Supl.1):41–45. https://doi.org/10.31260/RepertMedCir.01217372.1227